Amarin Corp. (AMRN) reported positive, statistically significant results from its first Phase 3 clinical trial of AMR101 Monday morning. The MARINE study, investigating AMR101 as a treatment for very high triglycerides, met its primary efficacy endpoints as defined in the clinical trial protocol and demonstrated a positive safety profile.
Amarin Corp. gapped open sharply higher Monday and is now up 2.19 at $5.74 on the highest volume of the year. The stock has surged to a new high for the year.
For comments and feedback contact: editorial@rttnews.com